A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

Abstract Background Equivalent efficacy and comparable pharmacokinetic, immunogenicity, and safety profiles of the biosimilar BAT1806/BIIB800 and reference tocilizumab (TCZ) in participants with moderate-to-severe rheumatoid arthritis (RA) have been reported up to week 24 (treatment period [TP] 1) o...

Description complète

Détails bibliographiques

Auteurs principaux:	Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, Shengyun Liu, Huaxiang Liu, Malgorzata Miakisz, Jieruo Gu, Lali Kilasonia, Mykola Stanislavchuk, Xiaolei Yang, Yinbo Zhou, Qingfeng Dong, Marian Mitroiu, Janet Addison, Mourad F. Rezk, Xiaofeng Zeng
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2024-09-01
Collection:	Arthritis Research & Therapy
Sujets:	Rheumatoid arthritis Biosimilar pharmaceuticals Tocilizumab Treatment switching
Accès en ligne:	https://doi.org/10.1186/s13075-024-03375-w
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!